Moderna Inc.

AI Score

0

Unlock

35.00
0.54 (1.57%)
At close: Jan 15, 2025, 9:35 AM

Moderna Statistics

Share Statistics

Moderna has 384.82M shares outstanding. The number of shares has increased by 0.51% in one year.

Shares Outstanding 384.82M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.11%
Owned by Institutions (%) n/a
Shares Floating 343.19M
Failed to Deliver (FTD) Shares 43
FTD / Avg. Volume 0%

Short Selling Information

The latest short interest is 39.49M, so 10.26% of the outstanding shares have been sold short.

Short Interest 39.49M
Short % of Shares Out 10.26%
Short % of Float 11.51%
Short Ratio (days to cover) 4.37

Valuation Ratios

The PE ratio is -8.06 and the forward PE ratio is -5.

PE Ratio -8.06
Forward PE -5
PS Ratio 5.55
Forward PS 3.6
PB Ratio 2.74
P/FCF Ratio -9.93
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Moderna Inc. has an Enterprise Value (EV) of 36.33B.

EV / Earnings -7.71
EV / Sales 5.3
EV / EBITDA -11.06
EV / EBIT -8.57
EV / FCF -9.5

Financial Position

The company has a current ratio of 3.42, with a Debt / Equity ratio of 0.

Current Ratio 3.42
Quick Ratio 3.36
Debt / Equity 0
Total Debt / Capitalization 0
Cash Flow / Debt 0
Interest Coverage -111.55

Financial Efficiency

Return on equity (ROE) is -0.34% and return on capital (ROIC) is -33.58%.

Return on Equity (ROE) -0.34%
Return on Assets (ROA) -0.26%
Return on Capital (ROIC) -33.58%
Revenue Per Employee 1.22M
Profits Per Employee -841.79K
Employee Count 5.60K
Asset Turnover 0.37
Inventory Turnover 23.23

Taxes

Income Tax 772.00M
Effective Tax Rate -0.2

Stock Price Statistics

The stock price has increased by -66.26% in the last 52 weeks. The beta is 1.69, so Moderna 's price volatility has been higher than the market average.

Beta 1.69
52-Week Price Change -66.26%
50-Day Moving Average 42.72
200-Day Moving Average 86.72
Relative Strength Index (RSI) 34.67
Average Volume (20 Days) 8.72M

Income Statement

In the last 12 months, Moderna had revenue of 6.85B and earned -4.71B in profits. Earnings per share was -12.34.

Revenue 6.85B
Gross Profit 2.15B
Operating Income -4.24B
Net Income -4.71B
EBITDA -3.28B
EBIT -4.24B
Earnings Per Share (EPS) -12.34
Full Income Statement

Balance Sheet

The company has 2.91B in cash and 1.24B in debt, giving a net cash position of 1.66B.

Cash & Cash Equivalents 2.91B
Total Debt 1.24B
Net Cash 1.66B
Retained Earnings 13.61B
Total Assets 15.80B
Working Capital 7.46B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.12B and capital expenditures -707.00M, giving a free cash flow of -3.83B.

Operating Cash Flow -3.12B
Capital Expenditures -707.00M
Free Cash Flow -3.83B
FCF Per Share -10.01
Full Cash Flow Statement

Margins

Gross margin is 31.47%, with operating and profit margins of -61.9% and -68.84%.

Gross Margin 31.47%
Operating Margin -61.9%
Pretax Margin -57.56%
Profit Margin -68.84%
EBITDA Margin -47.94%
EBIT Margin -61.9%
FCF Margin -55.86%

Dividends & Yields

MRNA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -35.8%
FCF Yield -28.84%
Dividend Details

Analyst Forecast

The average price target for MRNA is $69, which is 100.2% higher than the current price. The consensus rating is "Hold".

Price Target $69
Price Target Difference 100.2%
Analyst Consensus Hold
Analyst Count 18
Stock Forecasts

Scores

Altman Z-Score 3.97
Piotroski F-Score 2